CSIG-41 - Sensitizing cancer cells to Tumor Treating Fields (TTFields) by inhibition of PI3K

Friday, November 18, 2022

7:30 PM – 9:30 PM ET

Location: West/Central Hall

Author(s)

AK

Anat Klein-Goldberg, PhD

Novocure Ltd
Haifa, Israel
TV

Tali Voloshin, PhD

Novocure Ltd
Haifa, Israel
EZ

Efrat Zemer-Tov, MSc

Novocure Ltd
Haifa, Israel
RP

Rom Paz, MSc

Novocure Ltd
Haifa, Israel
LK

Lilach Koren, PhD

Novocure Ltd
Haifa, Israel
KW

Kerem Wainer-Katsir, PhD

Novocure Ltd
Haifa, Israel
AV

Alexandra Volodin, PhD

Novocure Ltd
Haifa, Israel
BK

Bella Koltun, PhD

Novocure Ltd
Haifa, Israel
BB

Boris Brant, PhD

Novocure Ltd
Haifa, Israel
YB

Yiftah Barsheshet

Novocure Ltd
Haifa, Israel
TK

Tal Kan

Novocure Ltd
Haifa, Israel
GC

Gadi Cohen

Novocure Ltd
Haifa, Israel
CD

Cfir David

Novocure Ltd
Haifa, Israel
TH

Tharwat Haj Khalil

Novocure Ltd
Haifa, Israel
AH

Adi Haber, PhD, MBA

Novocure Ltd
Haifa, Israel

Poster Presenter(s)

Moshe Giladi, PhD, MBA

Novocure Ltd
Haifa, Israel

Author(s)

UW

Uri Weinberg, PhD

Novocure Ltd
Haifa, Israel
YP

Yoram Palti, PhD

Novocure Ltd
Haifa, Israel

Tumor Treating Fields (TTFields) are alternating electric fields, which disrupt cellular process critical for cancer cell survival and tumor progression. TTFields therapy is approved for the treatment of glioblastoma (GBM) and unresectable malignant pleural mesothelioma, and is being tested in clinical studies for the treatment of other solid tumors, including ovarian cancer, non-small cell lung carcinoma (NSCLC), and hepatocellular carcinoma (HCC). The current study aimed to detect potential mechanisms that may reduce cellular sensitivity to TTFields, and target these pathways in order to re-sensitize the cells to TTFields. Cancer cells (Ovarian A2780, GBM U-87 MG, and NSCLC H1299) that display reduced sensitivity to TTFields were generated by continuous long-term TTFields application (7 or 13 days, depending on the cell line). A Luminex multiplex assay revealed activation of the PI3K/AKT/mTOR signaling pathway in these cells, with significant increases in phosphorylation levels of AKT and RPS6. This elevation was also observed by immunohistochemistry in tumor sections from N1S1 HCC tumor-bearing rats treated with TTFields relative to sham. Treatment of cells with PI3K inhibitors re-sensitized them to TTFields and downregulated the phosphorylation of AKT. Concomitant application of TTFields with the PI3K inhibitor alpelisib in mice orthotopically implanted with MOSE-L firefly luciferase (FFL) ovarian cancer cells resulted in enhanced efficacy, as determined by In Vivo Imaging System (IVIS) measurements of tumor volume. Overall, this study demonstrated that the PI3K/AKT/mTOR signaling pathway is involved in reduced cancer cell sensitivity to long-term application of TTFields, and that re-sensitization may be achieved with relevant inhibitors. The results provide a rationale for further examining the potential benefit of TTFields concomitant with PI3K inhibitors.